HER2 positive breast cancer.
Showing 1 - 25 of >10,000
Breast Cancer Female Trial (Pyrotinib and Trastuzumab)
Not yet recruiting
- Breast Cancer Female
- Pyrotinib and Trastuzumab
- (no location specified)
Sep 11, 2023
Early On-treatment Transcriptional Profiling as Predictor of
Recruiting
- HER2-positive Breast Cancer
- +2 more
- Trastuzumab (neoadjuvant)
- +2 more
-
Hospitalet de Llobregat, Barcelona, SpainInstitut Català d'Oncologia l'Hospitalet
Jun 12, 2023
Sentinel Lymph Node Biopsy in Initially Lymph Node-positive,
Completed
- Breast Cancer
- Sentinel Lymph Node
- Test cohort
-
Fuzhou, Fujian, ChinaChuan Wang
Nov 25, 2023
HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Miami (Discontinuation of Anti-HER-2 Maintenance
Recruiting
- HER2-positive Metastatic Breast Cancer
- Stage IV Breast Cancer
- Discontinuation of Anti-HER-2 Maintenance Treatment
-
Miami, FloridaUniversity of Miami
Jul 17, 2023
Breast Cancer, Brain Metastases, Radiotherapy Trial in Shanghai (Combination use of SRT with T-DXd)
Not yet recruiting
- Breast Cancer
- +2 more
- Combination use of SRT with T-DXd
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 14, 2023
HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without
Not yet recruiting
- HER2-positive Breast Cancer
- Standard of Care Adjuvant Breast Radiation
- Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
- (no location specified)
Jan 20, 2023
t Pathologic Complete Response Observed in HER2 Positive Breast
Completed
- HER2+ Breast Cancer
-
Rawalpindi, Punjab, PakistanRawalpindi Medical University
Jun 26, 2023
Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
Recruiting
- Breast Cancer
- Whole breast irradiation +/- tumor bed boost
-
Seoul, Korea, Republic ofSamsung Medical Center
May 30, 2023
Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,
Active, not recruiting
- Breast Cancer
- HER2-positive Breast Cancer
- Albumin paclitaxel+trastuzumab+pyrrolitinib
- Docetaxel+Carboplatin+trastuzumab+Parstuzumab
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Jun 23, 2023
Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)
Recruiting
- Breast Cancer With Brain Metastases
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023
HER-2 Positive Breast Cancer Trial in Tianjin (TCbHP VS ddEC-THP)
Recruiting
- HER-2 Positive Breast Cancer
- TCbHP VS ddEC-THP
-
Tianjin, Tianjin, ChinaBreast Oncology, Tianjin Medical University Cancer Institute and
May 15, 2023
Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and
Recruiting
- Early-stage Breast Cancer
- +4 more
- Trastuzumab and nelatinib
- Trastuzumab and Parstuzumab
-
Guangzhou, ChinaSun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023
Breast Cancer Trial in Xi'an (Disitamab Vedotin plus pyrotinib or naratinib)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin plus pyrotinib or naratinib
-
Xi'an, Shaanxi, ChinaXi'an International Medical Center Hospital
Aug 27, 2023
HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)
Completed
- HER2-positive Breast Cancer
- HS022
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Province People's Hospital (First Affiliated Hospital of
Oct 25, 2023
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2
Recruiting
- HER2-positive Breast Cancer
- Early-stage Breast Cancer
- pyrotinib combined with Capecitabine
- treatment of physician's choice
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 6, 2023
Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))
Recruiting
- Advanced Breast Cancer
- +2 more
- Trastuzumab Emtansine (T-DM1)
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023
HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)
Not yet recruiting
- HER2-positive Breast Cancer
- 68Ga/131I-SGMIB-5F7
-
Shanghai, ChinaHuashan Hospital
Aug 1, 2023
Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)
Not yet recruiting
- Breast Cancer
- HER2-positive Breast Cancer
-
São Paulo, BrazilCentro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023
HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Breast Cancer
- Trastuzumab deruxtecan
-
Amsterdam, NetherlandsAntoni van Leeuwenhoek
Aug 7, 2023
HER2-positive Breast Cancer Trial in Shanghai (SYSA1901, Pertuzumab, Trastuzumab)
Recruiting
- HER2-positive Breast Cancer
- SYSA1901
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 8, 2023
Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Not yet recruiting
- HER2-positive Breast Cancer
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Sep 28, 2022
HER2-positive Breast Cancer Trial (Thero2-01S22, Placebo)
Not yet recruiting
- HER2-positive Breast Cancer
- Thero2-01S22
- Placebo
- (no location specified)
Jan 13, 2023
Ado-trastuzumab Emtansine-Induced Peripheral Neuropathy in
Recruiting
- Breast Neoplasm
-
Rochester, MinnesotaMayo Clinic Minnesota
Jun 12, 2023